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Abstract
Background: Intensive malaria control may have additional benefits beyond reducing the incidence of
symptomatic malaria. We compared antibiotic treatment of children before and after the implementation of highly
effective malaria control interventions in Tororo, a historically high transmission area of Uganda.
Methods: Two successive cohorts of children, aged 0.5 to 10 years, were followed from September 2011 to
October 2019 in a dedicated study clinic. Universal distribution of long-lasting insecticidal nets was conducted in
2013 and 2017. Sustained indoor residual spraying of insecticide (IRS) was initiated in December 2014. Generalized
linear mixed-effects models were used to compare the incidence of antimalarial and antibiotic treatments before
and after vector control measures were implemented.
Results: Comparing the period prior to the implementation of IRS to the period after IRS had been sustained for 4–
5 years, the adjusted incidence of malaria treatments decreased from 2.68 to 0.05 per person-year (incidence rate
ratio [IRR] = 0.02, 95% CI 0.01–0.03, p < 0.001), and the adjusted incidence of antibiotic treatments decreased from
4.14 to 1.26 per person-year (IRR = 0.30, 95% CI 0.27–0.34, p < 0.001). The reduction in antibiotic usage was
primarily associated with fewer episodes of symptomatic malaria and fewer episodes of fever with sub-microscopic
parasitemia, both of which were frequently treated with antibiotics.
Conclusions: In a historically high transmission setting, the implementation of highly effective vector control
interventions was followed by a marked reduction in antibiotic treatment of children. This added benefit of malaria
control could have important implications for antibiotic prescribing practices, efforts to curtail antimicrobial
resistance, and health system costs.
Keywords: Malaria control, Pediatric infectious diseases, Antibiotic prescriptions, Malaria, Antibiotic usage,
Prevention, Pediatrics
Background
Intensive malaria control, including widespread distribu-
tion of long-lasting insecticidal nets (LLINs) and indoor
residual spraying (IRS) of insecticides, can significantly
lower the burden of malaria in endemic settings [1].
Vector control interventions aimed at reducing trans-
mission intensity can reduce malaria burden, but redu-
cing malaria may have additional health benefits beyond
those attributable to malaria alone [2, 3]. We hypothe-
sized that intensive vector control in a previously high-
transmission setting, resulting in the near elimination of
malaria, would be associated with reduced antibiotic use
among children.
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Acute bacterial and viral infections are common in
malaria-endemic settings, and malaria may affect the risk
of co-infection with these other pathogens [4, 5]. More-
over, decisions about the use of antibiotics during clin-
ical encounters are inextricably entwined with the
burden of malaria in a community [6]. This interrela-
tionship is most apparent during febrile clinical encoun-
ters, but even infection with malaria parasites in the
absence of fever (i.e., asymptomatic parasitemia) may
have an effect on the likelihood of clinical presentation
resulting in the use of antibiotics. The widespread use of
antibiotics to treat non-malarial infections and the con-
comitant use of antibiotics in patients treated with anti-
malarial drugs may be unnecessary and may contribute
to the selection of antimicrobial resistance, which is a
major public health threat [7–9]. The effect of malaria
control on malaria-specific outcomes and the interaction
between malaria diagnoses and antibiotic use have been
well-researched, but evidence on the use of antibiotics in
the context of successful population-level malaria con-
trol is limited.
This observational study explores the temporal rela-
tionship between the implementation of highly effective
malaria control interventions and antibiotic usage in two
sequential cohorts of children aged 0.5 through 10 years
in Tororo, Uganda. Potential mechanisms for observed
trends are explored by stratifying analyses according to
the history of fever and the presence or absence of mal-
aria parasites on the day antibiotics were prescribed and




The study took place in Nagongera sub-county, Tororo
district, Uganda, historically a high transmission setting
currently under intensive vector control, as previously
described [1]. Universal distribution of free LLINs oc-
curred in November 2013 and May 2017. IRS with the
carbamate bendiocarb began in the entire Tororo district
in December 2014, with additional rounds in June and
November 2015. In June 2016, the IRS formulation was
changed to organophosphate pirimiphos-methyl (Actel-
lic), with repeated rounds in June 2017, June 2018, and
March 2019.
Cohort enrollment and follow-up procedures
Figure 1 summarizes two sequential dynamic cohorts
that contributed data to this study. Detailed procedures
have been published elsewhere [1]. In brief, children
aged 6 months through 10 years of age were enrolled
from randomly selected households. The first cohort
(PRISM 1) included 107 households and 385 children
followed from August 2011 to September 2017. The
second cohort (PRISM 2) included 80 households and
306 children followed from October 2017 to October
2019. Thirty-three households and 94 children enrolled
in the first cohort were also included in the second. Both
cohorts were dynamic such that all newly eligible chil-
dren were enrolled, and participants that reached 11
years of age were excluded from further follow-up. Par-
ents/guardians were encouraged to bring their child to a
dedicated study clinic open every day any time they were
ill. Reported seeking of care outside the study clinic for
acute illnesses was very rare and comparable across both
cohorts (0.2% in PRISM 1 versus 0.5% of annual re-
ported illnesses in PRISM 2). Participating households
received free LLINs sufficient to cover all study partici-
pants at enrollment and at any time on request at the
clinic. Routine visits were conducted in the clinic for all
children every 3 months until November 2014, and every
month thereafter. The same study clinicians provided
care for children throughout both cohorts, drawing from
the Uganda Clinical Guidelines (UCG) provided by the
Ministry of Health. For both cohorts, detailed medical
records were maintained at all visits using the same
standardized approach, including history, physical exam,
diagnoses, and all medications prescribed.
Definition of malaria and estimates of parasitemia
At all study clinic visits, children with a history of fever
in the previous 24 h or a tympanic temperature ≥ 38.0 °C
had an urgent thick blood smear read using light mi-
croscopy. If the blood smear was positive, the child was
diagnosed with clinical malaria and managed according
to national guidelines. At each routine visit, in addition
to microscopy, blood was also collected from all cohort
participants for the detection of malaria parasites by mo-
lecular methods. The molecular methods employed were
loop-mediated isothermal amplification (LAMP) in the
first cohort and quantitative PCR (qPCR) in the second
cohort as previously described [1, 10]. Children with
asymptomatic parasitemia (either by microscopy or mo-
lecular methods) were not treated with antimalarials, in
accordance with local guidelines. At the time of each
clinic visit, children were classified as having (1) no para-
sitemia, (2) sub-microscopic parasitemia, or (3) micro-
scopic parasitemia. If there was no blood smear or
molecular test (LAMP or qPCR) performed on the day
antibiotics were prescribed, parasite status was classified
based on linear interpolation of data from prior and sub-
sequent visits. Briefly, for days in which there were no
lab measurements, parasitemia was defined by connect-
ing flanking values of the measured parasite counts with
line segments and taking the parasite density on the un-
measured day of interest (i.e., the day antibiotics were
prescribed) to be the value along that line. Parasite sta-
tus for days without microscopic or molecular tests was
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made using a threshold of interpolated estimates with
the classification of days with ≥ 16 parasites/mL as
“microscopic,” from ≥ 1 to < 16 parasites/mL as “sub-
microscopic,” and < 1 parasite/mL as “no parasitemia.”
Additional file 1 contains the full algorithm and flow
charts for the parasite density assumptions for the linear
interpolation (Additional file 1: Fig. S1) and the classifi-
cation of parasite status (Additional file 1: Fig. S2).
Definition of antibiotic treatment and diagnoses
If an antibiotic was prescribed at a clinic visit, this was
considered an incident episode of antibiotic treatment.
Fig. 1 Flow diagram of the cohort studies
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We focused on oral and parental formulations of medi-
cations used predominantly for their antibacterial prop-
erties; antifungal, antiviral, and antiparasitic medications
were excluded, as were non-systemic antibiotics such as
topical formulations or drops. Based on standardized
diagnostic codes, the primary reasons for prescribing an-
tibiotics were divided into infections by system (e.g.,
upper respiratory, skin/soft tissue, ear/throat/dental).
Antibiotic classes were matched directly to diagnostic
codes where possible (e.g., amoxicillin for acute otitis
media = ear/throat/dental). If there was no direct match
to a category, the best match was determined using asso-
ciated symptoms (i.e., amoxicillin for ear pain = ear/
throat/dental). An “other” category was used if there
remained uncertainty as to the reason for the antibiotic
or for uncommon occurrences.
Statistical analysis
Locally weighted scatterplot smoothing (LOWESS) was
used to show trends in malaria and antibiotic treatments
over time. The primary outcomes of interest were the
incidence of malaria and antibiotic treatments per
person-year of observation in the cohort studies. The
primary exposure of interest was calendar time divided
into three periods: pre-IRS (September 2011 through
November 2014), years 1–3 of IRS (December 2014
through November 2017), and years 4–5 of IRS (Decem-
ber 2017 through October 2019).
Mixed-effects Poisson regression was used to estimate
the risk of a malaria or antibiotic treatment per child per
day during each exposure time period [11]. Incidence
per person-year was calculated by multiplying incidence
per person-day by 365.25. Models were adjusted for age,
gender, calendar month fixed effects (to capture seasonal
trends), included household- and individual-level ran-
dom intercepts, and robust standard errors to account
for autocorrelated outcomes. An additional analysis fit
the same model for antibiotic treatments stratified by six
strata representing fever (yes/no) and parasite status
(none, sub-microscopic, microscopic). To assist in the
interpretation of the magnitude of the trends, measures
of association are reported as both incidence rate ratios
(IRR) and incidence rate differences (IRD) with 95% con-
fidence intervals (CIs). Statistical analyses were con-
ducted at the 5% significance level and were performed
using STATA 14 (College Station, TX).
Results
Changes in the incidence of malaria treatments following
implementation of IRS
Prior to the implementation of IRS, malaria treatments
followed a seasonal pattern with two annual peaks and
an adjusted average of 2.68 treatments per person-year
(Fig. 2 and Table 1). In the first 3 years following the
implementation of IRS, there was a 75% reduction in the
incidence of malaria treatments (IRR = 0.25, 95% CI 0.21
to 0.28; p < 0.001) with peaks occurring at the time
rounds of IRS being delivered. In years 4–5 following
the implementation of IRS, treatments for malaria were
nearly eliminated with an adjusted incidence of 0.05 per
person-year, corresponding to a 98% reduction in the in-
cidence of malaria and 2.63 fewer malaria treatments per
child per year compared to pre-IRS (IRD = 2.63, 95% CI
2.36 to 2.90; p < 0.001).
Changes in the incidence of antibiotic treatments
following implementation of IRS
Prior to the implementation of IRS, the average adjusted
incidence of antibiotic treatments was 4.14 per person-
year (Table 2). In the first 3 years following the imple-
mentation of IRS, there was a 53% reduction in the inci-
dence of antibiotic treatments (IRR = 0.47, 95% CI 0.43
to 0.52; p < 0.001). In years 4–5 following the implemen-
tation of IRS, the adjusted incidence of antibiotic treat-
ments further reduced by 70% from pre-IRS levels (IRR
= 0.30, 95% CI 0.27 to 0.34; p < 0.001) corresponding to
almost 3 fewer antibiotic treatments per person-year
(IRD = 2.88, 95% CI 2.54 to 3.21; p < 0.001)
In the stratified analysis, there was a small but signifi-
cant increase in years 4–5 in the incidence of antibiotic
treatments given when children were afebrile without
parasitemia compared to the pre-IRS period (IRD = 0.39;
95% CI 0.27 to 0.51; p < 0.0001). All other categories ex-
perienced reductions in the incidence of antibiotic treat-
ments 4–5 years after the implementation of IRS. The
most marked declines were in the categories of children
who were febrile with sub-microscopic parasitemia (IRD
= 1.15, 95% CI 1.02 to 1.27, p < 0.001) and had clinical
malaria (IRD = 1.12, 95% CI 0.99 to 1.25; p < 0.001).
There were more modest declines among children in the
other categories: febrile with no parasitemia (IRD = 0.13,
95% CI 0.24 to 0.01; p = 0.036), afebrile with sub-
Fig. 2 Changes in antibiotic and malaria treatments over time. Daily
estimates of incidence generated using LOWESS smoothing
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microscopic parasitemia (IRD = 0.31, 95% CI 0.38 to
0.24; p < 0.001), and afebrile with microscopic parasit-
emia (IRD = 0.49, 95% CI 0.57 to 0.40; p < 0.001)
(Fig. 3).
Changes in diagnoses and types of antibiotics following
the implementation of IRS
Most antibiotic treatments were given for upper respira-
tory infections (URI), which constituted 84.0% of diagno-
ses and accounted for 3.52 antibiotic treatments per
child per year pre-IRS (Fig. 4). Both the incidence and
proportion of antibiotics given for URIs decreased fol-
lowing IRS, comprising 70.1% of visits for which antibi-
otics were prescribed and an incidence of 0.91
treatments per child per year in years 4–5. The propor-
tion of antibiotics prescribed for skin/soft tissue infec-
tions increased (5.0 to 11.9% of all prescriptions by years
4–5), but the incidence remained relatively unchanged
(0.21 to 0.16 per person-year). There was a similar pat-
tern for gastrointestinal infections. The incidence and
proportion of antibiotic treatments given for urinary
tract infections (UTIs) declined over the study period,
while treatments for pneumonia increased in both inci-
dence and proportion. Overall, amoxicillin was the most
common antibiotic prescribed, accounting for 92.0% of
antibiotic prescriptions and 3.86 per child per year pre-
IRS (Fig. 5). Mirroring the pattern for URIs, amoxicillin
prescriptions also decreased in both incidence and pro-
portion following IRS, comprising 62.6% of antibiotic
prescriptions and 0.81 amoxicillin treatments per child
per year in years 4–5. Ampicillin plus cloxacillin in-
creased in both relative proportion (from 2.7 to 29.9%)
and incidence (from 0.12 to 0.39 treatments per child
per year) by years 4–5. The use of other antibiotic types
was uncommon.
Discussion
In this highly malaria-endemic region of Uganda, suc-
cessful malaria control with LLINs plus IRS was followed
by almost complete elimination of symptomatic malaria
and a substantial reduction in the incidence of antibiotic
treatments among children 0.5 to 10 years of age. In-
deed, in the 4–5 years following the implementation of
IRS, children received nearly three fewer antibiotic treat-
ments per year, a 70% reduction compared to the pre-
IRS period. These results provide further evidence that
in highly endemic settings, successful malaria control ef-
forts can have substantial health benefits for children be-
yond those directly attributable to reducing the burden
of symptomatic malaria.
In addition to the important health benefits to the
children and the socioeconomic benefits to families, the
magnitude of reduced antibiotic treatments demon-
strated in this study has important implications for
health systems in malaria-endemic settings. Countries
like Uganda struggle with training and retaining staff to
ensure quality care and meet patient needs [12]. Inten-
sive malaria control with LLINs and IRS in this region
was associated with 2.6 fewer treatments for malaria and
nearly 2.88 fewer antibiotic treatments per child per





Incidence* IRR (95% CI)† p-
value
IRD (95% CI)† p-
valueCrude Adjusted †
Pre-IRS 2515 843.0 2.98 2.68 Reference group Reference group
Years 1–3 of IRS 455 639.3 0.71 0.66 0.25 (0.21, 0.28) < 0.001 − 2.02 (− 2.27, − 1.78) < 0.001
Years 4–5 of IRS 27 489.4 0.06 0.05 0.02 (0.01, 0.03) < 0.001 − 2.63 (− 2.90, − 2.36) < 0.001
Abbreviations: IRR incidence rate ratio (incidence in the comparison group/incidence in the reference group), IRD incidence rate difference (incidence in the
comparison group − incidence in the reference group), IRS indoor residual spraying
*Treatments per person-year
†Estimates calculated using mixed-effects Poisson regression with robust standard errors. Models included individual- and household-level random intercepts and
were adjusted for age, gender, and calendar month fixed-effects





Incidence* IRR (95% CI)† p-
value
IRD (95% CI)† p-
valueCrude Adjusted†
Pre-IRS 3534 843.0 4.19 4.14 Reference group Reference group
Years 1–3 of IRS 1165 639.3 1.82 1.96 0.47 (0.43, 0.52) < 0.001 − 2.18 (− 2.48, − 1.88) < 0.001
Years 4–5 of IRS 636 489.4 1.30 1.26 0.30 (0.27, 0.34) < 0.001 − 2.88 (− 3.21, − 2.54) < 0.001
Abbreviations: IRR incidence rate ratio (incidence in the comparison group/incidence in the reference group), IRD incidence rate difference (incidence in the
comparison group − incidence in the reference group), IRS indoor residual spraying
*Treatments per person-year
†Estimates calculated using mixed-effects Poisson regression with robust standard errors. Models included individual- and household-level random intercepts and
were adjusted for age, gender, and calendar month fixed-effects
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year. At a health system level, this could result in a sub-
stantial reduction in patient volume, staffing needs, and
costs associated with care. Furthermore, the high num-
ber of antibiotic treatments averted, mostly amoxicillin,
could reduce selection pressure and help slow the spread
of antimicrobial resistance which is a major public
health threat in Uganda and elsewhere [13, 14].
There are multiple plausible mechanisms explaining
the association between effective vector control leading
to reduced malaria burden and an accompanying reduc-
tion in antibiotic use among children. As malaria burden
decreased precipitously, the incidence of antibiotic treat-
ments for all categories of children with parasitemia de-
creased compared to the period before IRS was
implemented. This decrease was most marked among fe-
brile children, such as those diagnosed with clinical mal-
aria or were febrile with sub-microscopic parasitemia.
There was a more modest decrease for children with
parasitemia who were afebrile. This pattern of greater
decreases in antibiotics prescribed for febrile versus
afebrile children was observed across all categories of
parasitemia. In general, patients diagnosed with malaria
may also be prescribed antibiotics because of concern
for other co-occurring illnesses. Indeed, in this study,
40% of children treated for malaria were also given anti-
biotics prior to the implementation of IRS, which de-
creased to 20% after the implementation of IRS. Thus,
reducing the incidence of malaria may reduce suscepti-
bility to concomitant illnesses and limit opportunities to
prescribe concomitant antibiotics [5]. Sub-microscopic
parasitemia may induce symptoms, including fever, trig-
gering clinic visits that may result in an antibiotic pre-
scription, particularly if the parasitemia is below the
level of detection by standard laboratory tests and the
clinician is unaware that the patient is infected with mal-
aria. Other contributing factors that play into a
Fig. 3 Incidence rate difference in antibiotic treatments compared to pre-IRS levels stratified by fever and parasitemia status. IRS, indoor
residual spraying
Fig. 4 Changes in diagnostic category for antibiotic treatments over time
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clinician’s decision to prescribe an antibiotic may be in-
dependent of clinical symptoms. In cases where a clin-
ician is unsure of the utility of antibiotics, clinicians
often face an expectation to provide some form of inter-
vention or treatment as a conservative measure or to
meet patient demands [15]. Perceptions of risk for the
progression to severe disease and trust within the
clinician-patient relationship also play important roles
[16].
As malaria burden declined in the population follow-
ing IRS, one might have expected an increase in the inci-
dence of antibiotic treatments among the febrile
children who tested negative for malaria by microscopy
as has been found in other low transmission settings in
Uganda [6]. However, we found that the incidence of
antibiotic treatment decreased slightly for febrile chil-
dren without parasitemia and increased for afebrile chil-
dren without parasitemia following the implementation
of IRS. It is possible that clinicians felt pressured to pro-
vide antibiotics for afebrile children, even for those with
lower severity illnesses such as viral URIs for which anti-
biotics are typically not recommended, since they had
nothing else to offer. On the other hand, febrile children
received an urgent blood smear according to the study
protocol. This diagnostic test may have fulfilled the ex-
pectation to provide some sort of intervention and
allowed the clinician to forgo an antibiotic prescription.
These results contrast, however, with multiple studies
showing antibiotics are typically prescribed more fre-
quently with negative malaria tests [6, 17–19]. In this co-
hort study, repeated contact may have allowed clinicians
to develop stronger relationships with families, making it
easier to avoid antibiotics overall. It is also possible that
the children may have become healthier over time solely
due to the rigorous free health care provided as a part of
the research study or that exposure to other bacterial or
viral illnesses in the community, which we did not meas-
ure, may have also been declining. Future research is
needed to explore antibiotic prescription practices rela-
tive to parasitemia status and fevers in more typical
clinic settings.
Another potential mechanism underlying the reduced
antibiotic treatments found here may be reduced suscep-
tibility to co-infection with acute bacterial, viral, or other
parasitic infections as a result of decreased parasitemia
[20]. An association between malaria and serious bacter-
ial infections has been documented among severely ill
children in hospital settings [21]. While less well studied,
malaria may also increase the risk of less severe infec-
tions seen in outpatient settings through indirect effects
on the immune system [20], anemia [3], birth weight
[22, 23], and nutrition/growth [24]. Indeed, malaria in-
fections at any density have been associated with serious
health outcomes [25]. Furthermore, malaria control may
improve overall child health by mitigating the socioeco-
nomic costs incurred by the household due to malaria-
related illness [26]. Finally, malaria control targeting
mosquitoes may decrease the risk of other vector-borne
illnesses, such as arboviruses or other parasitic infec-
tions, though studies on these types of pathogens are
limited. This could be one potential explanation for the
decrease in the incidence of antibiotics among children
who were febrile and non-parasitemic in our study, such
that intensive malaria control (i.e., IRS) may have re-
duced the risk of other vector-borne illnesses and thus
avoiding another opportunity to prescribe antibiotics for
a febrile non-malarial illness.
Fig. 5 Changes in antibiotic type used for antibiotic treatments over time
Krezanoski et al. BMC Medicine          (2021) 19:294 Page 7 of 9
This study had several limitations inherent with obser-
vational studies making “before and after” comparisons.
First, we lacked a contemporary control group which did
not receive intensive malaria control, thus limiting our
ability to make causal inferences. Second, there are limi-
tations with external validity given that our study partici-
pants were enrolled in a research study and provided
more rigorous care than is typically available in
resource-limited settings. However, the extended follow-
up and the consistency inherent in clinical management
by only a few providers using highly standardized proce-
dures are benefits of the cohort study design. Third, our
analyses did not adjust for secular trends in malaria and
antibiotic treatments, as there is a complex relationship
between these and seasonal variations making accurate
modeling of these trends challenging. Though we are
unaware of other significant changes in the district, it is
possible that other health programs or other changes in
the study area could explain the decrease in antibiotic
use over time. Finally, the stratified analysis partially re-
lied on estimates of daily parasite status interpolated
from prior and subsequent lab results, potentially intro-
ducing bias.
Conclusion
Intensive malaria control in this previously high trans-
mission setting was associated with a significant decline
in the use of antibiotics, as well as malaria treatments, in
a closely followed cohort of children. We found that in-
vestments in malaria control may have broader health
benefits for children beyond malaria. Future studies
should investigate the association between malaria con-
trol and antibiotic prescribing practices in other settings
to further explore the impact on health systems and to
inform strategies to mitigate the overuse of antibiotics
and the threat of antimicrobial resistance in malaria-
endemic settings.
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